BusinessBioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with AchondroplasiaBy Nasdaq OMXDec 12, 2016, 1:29 PM UTC
BusinessBioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 MeetingBy Nasdaq OMXOct 19, 2016, 9:01 PM UTC
